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Abstract
A physical hydrogel cross-linked via the host-guest interactions of cucurbit[8]uril and utilised as an implantable drug-
delivery vehicle for the brain is described herein. Constructed from hyaluronic acid, this hydrogel is biocompatible
and has a high water content of 98%. The mechanical properties have been characterised by rheology and compared
with the modulus of human brain tissue demonstrating the production of a soft material that can be moulded into
the cavity it is implanted into following surgical resection. Furthermore, effective delivery of therapeutic compounds
and antibodies to primary human glioblastoma cell lines is showcased by a variety of in vitro and ex vivo viability and
immunocytochemistry based assays.
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1. Introduction
Glioblastoma (GB) is the most common primary ma-
lignant brain cancer in adults and one of the most ag-
gressive cancers. The median survival in the general pa-
tient population is just 4.6 months.[1] Even in optimally
treated patients the median survival is 14 months with a
26% two year survival rate.[2, 3, 4, 5] GB infiltrates the
brain tissue diffusely making complete surgical excision
impossible.[6] The majority of patients (90%) will suffer
recurrence within 2 cm of the resection cavity due to the
presence of residual disease.[7]
Current standard of care involves surgical resection
of the tumour, concomitant radiotherapy and alkylating
chemotherapy (CRT), followed by adjuvant chemotherapy.[2]
TMZ is the major chemotherapeutic agent used to treat
GB as it is one of the few molecules that readily cross the
blood-brain barrier (BBB).[8] Following uptake into the
brain, TMZ is hydrolyzed into its active form MTIC en-
abling methylation of the O-6 position on guanine residues,
resulting in cytotoxic DNA damage.[9] However, TMZ also
degrades to MTIC in the blood stream which does not
cross the BBB and can cause systemic toxicity, including
bone marrow suppression.[10] Such toxicity sometimes re-
quires dose reduction or termination of concomitant or ad-
juvant chemotherapy. Therefore, despite the use of TMZ,
∗Corresponding author
Email address: oas23@cam.ac.uk (Oren A. Scherman)
1These authors contributed equally to this work
surgical resection and radiotherapy as standard of care,
patient survival rates remain poor.
At the end of surgery, a localised and sustained delivery
of patient-tailored chemotherapy to the resection cavity
walls could significantly enhance patient survival oppor-
tunities by circumventing the BBB to eradicate the local,
residual disease. A recent clinical trial (NCT01310868)
evaluated the use of local DNA cross-linking chemother-
apy (carmustine) in patients undergoing advanced surgi-
cal resection.[11] The trial delineates the benefit of anti-
neoplastic effects from the increasingly aggressive neuro-
oncological care patients receive, determining that the car-
mustine wafer added no additional patient benefit follow-
ing fluorescence-guided surgery.[12] The carmustine im-
plant takes the form of drug-loaded wafers produced from
1,3-bis-(p-carboxyphenoxy)propane (CPP) and sebacic acid
(SA) monomers (20:80 molar ratio) connected with anhy-
dride bonds. The rigid wafers (Gliadel R©) are administered
at the end of surgery to the tumour bed.[13, 14] Such im-
plants have the potential to cause a mechanical mismatch
between the implant and surrounding tissue that could re-
sult in encapsulation of implants by fibrous tissue and a
foreign body reaction. [15, 16] Once in contact with phys-
iological fluid, carmustine is released through erosive dis-
solution of the matrix in a 2–3 week period.[17, 18, 19, 20]
The permanent shape and stiffness of the implant (14 mm
diameter, 1 mm depth) compromise tissue–wafer contact,
which limits tumour penetration by the carmustine.[3, 21,
22, 19] Due to the strong lipophilicity of carmustine, facile
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Figure 1: The hydrogel (blue) may be implanted in a tumour resection cavity via a syringe/needle. The hydrogel acts as a drug reservoir,
delivering active chemotherapies through the cavity wall into the recurrence zone. The hydrogel consists of a hyaluronic acid functionalised
with phenylalanine terminated peptides that bind in a 2:1 fashion with the CB[8] host providing shear-responsive crosslinks that allow for
injection.
diffusion through cell membranes and into tissue is easily
achievable. However, this also results in a rapid loss of car-
mustine from the brain into systemic circulation, forming
sharp concentration gradients that span just micrometer
distances from the implant site.[19] Since disease recur-
rence occurs within 2 cm of the resection cavity, the depth
of carmustine penetration is insufficient and therefore me-
dian survival rates remain limited.[21, 23] The use of this
local treatment remains under scrutiny because therapeu-
tic efficacy remains unproven; the wafers are associated
with an increased risk of wound infection, chemical menin-
gitis and cerebral edema and its use can preclude patients
participating in clinical trials.[21, 12] A major reason for
the lack of benefit is the relative stiffness of the polyanhy-
dride matrix leading to poor apposition with brain tissue
and a propensity to move with cavitary expansion.
To address the current local delivery limitations, we
set out to establish design criteria for an alternative drug-
delivery platform. These criteria are listed below:
1. The delivery vehicle should be mechanically softer
than surrounding brain tissue. This would prevent serious
adverse side effects resulting from contact with a hard im-
plant. A stiff implant would hamper contact interactions
and therapeutic efficacy of the delivery device.
2. The material must be malleable, mouldable and
injectable. The substance should be spreadable around the
resection cavity but stiff and adherent enough to maintain
its shape and position once applied to the treatment area.
The material should also be rapidly self healing to enable
immediate retention of the material and its cargo upon
injection via a syringe into the cavity.
3. Cargo loading and delivery properties should be
readily tailorable. Surgical staff should be able to eas-
ily formulate the delivery vehicle with appropriate cargo.
This is particularly relevant for heterogeneous disease such
as GB owing to the diverse cell population; a range of ther-
apeutic resistances can be found within a single tumour
mass.[6]
4. The delivery vehicle must be biocompatible and
biodegradable.
Hydrogels are a class of materials that can satisfy all
of these criteria.[24] Hyaluronic acid (HA), a component
of the brain’s extracellular matrix, can be readily func-
tionalised with peptide residues (cysteine-phenylalanine,
CF) as we have previously reported.[25] The phenylalanine
side chain can form 2:1 homoternary host-guest complexes
with cucurbit[8]uril (CB[8]) resulting in a physically cross-
linked HA-CF hydrogel as illustrated in Figure 1. This
polysaccharide functionalization methodology was further
chosen as a degradation pathway for the hydrogel to be re-
moved from the brain is required. This should occur at a
slower rate than the required time period for drug-delivery.
2. Materials and Methods
All starting materials were purchased from Sigma Aldrich
and used as received unless stated otherwise. Rheology
was performed using a TA instruments DHR 2 rheometer.
Dynamic oscillatory strain amplitude sweep measurements
were conducted at a frequency of 10 rad s-1. Dynamic os-
cillatory frequency sweep measurements were conducted
at a 1% oscillation strain. All measurements were per-
formed using a 40 mm parallel plate geometry with a gap
of 0.500 mm and analysed using TA Instruments TRIOS
software. Live cell imaging was performed with a Leica
TSP8 Confocal Laser Scanning Microscope fitted with a
full live cell chamber with temperature, CO2 and humidity
control, a SuperZ Galvo Stage and Auto-Focus LAS AF.
MTT viability results were obtained from absorbance spec-
tra measured with a Bio-Tek Instruments ELISA µQuant
Multiscan and analysed with Gen software. Fluorescent
imaging of cell monolayers and tissue slices was performed
with a Leitz DMRB Fluorescence microscope with Leica
AS F software. Tissue samples were sliced to 15 µm with a
Leica Cryotome CM3050 S. UV/vis spectroscopy was per-
formed by using a Varian Cary 4000 UV-vis spectropho-
tometer. Unless otherwise stated, primary antibodies were
purchased from Abcam and these were rabbit IL6, rabbit
TNF receptor 1, rabbit IL1 beta, mouse Nestin, mouse
SOX2. Secondary antibodies were purchased from Life
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Technologies and these were anti-mouse Alexa fluor 488
IgG and anti- rabbit Alexa fluor 647 IgG. Hyaluronic acid
from Streptococcus zooepidemicus (1.5 MDa), the highest
molecular weight commercially available was purchased.
1H-NMR (500 MHz) and 13C-NMR (125 MHz) spectra
were recorded in D2O, using a Bruker 500 MHz DCH
Cryoprobe Spectrometer. Dialysis of the polymers was
carried out by placing the reaction solutions into a dial-
ysis tube (Spectrum Labs, Spectra/Por, standard grade
regenerated cellulose dialysis membrane 6, MWCO 15,000
Daltons) which was subsequently submerged in specified
aqueous solutions. The external solutions were stirred at
room temperature and replaced periodically over a 72 h
time period (ca. 4-5 times daily). The dialysed polymer
solution was then transferred into a round bottom flask,
frozen in a dry ice/acetone bath and lyophilized on a Vir-
Tis BenchTop Freeze Drier to yield fluffy solid materials.
2.1. FC-CF peptide[25]
As previously published, Boc-L-phenylalanineN -hydroxy-
succinimide ester (Boc-Phe-OSu, 5.00 g, 13.8 mmol) was
dissolved in DMF (50 mL) and triethylamine (5.75 mL,
41.4 mmol, 3 eq.) added. L-cystine dihydrochloride (1.72 g,
5.50 mmol, 0.4 eq), was added to the solution and stirred
overnight. The solution was diluted with ethyl acetate
and water and then acidified with 1.0 M HCl. The aque-
ous layer was extracted and the organic layer was washed a
further four times with acidified water. The organic layer
was then collected and dried with magnesium sulfate, fil-
tered and concentrated to dryness in vacuo to yield a yel-
low solid. The crude residue was dissolved in a minimal
amount of chloroform and recrystallised overnight. The
white crystals were collected by vacuum filtration, imme-
diately suspended in dichloromethane (50 mL), and 4N
hydrogen chloride in dioxane (50 mL) was added. The re-
action mixture clarified on addition of the hydrogen chlo-
ride solution and the product precipitated within 2 h. The
reaction mixture was concentrated to dryness in vacuo and
the white solid suspended in diethyl ether. The suspen-
sion was stirred until the precipitate appeared finely dis-
persed and then collected by vacuum filtration. Copious
amounts of diethyl ether were washed over the solid, which
was then dried under high vacuum and stored at 4oC. 3,3’-
disulfanediylbis(2-(2-amino-3-phenylpropanamido)propanoic
acid) dihydrochloride Yield: 2.510 g, 75 %;
1H-NMR (D2O, 500 MHz) δ (ppm) = 7.40-7.22 (6H,
m, Ar-H ), 7.22-7.15 (4H, m, Ar-H ), 4.65-4.55 (2H, dd,
J = 8.4 Hz, 5.1 Hz, C-H ), 4.27-4.18 (2H, dd, J = 7.0 Hz,
7.0 Hz, C-H ), 3.25-3.07 (6H, m, HC-H ) 2.95-2.85 (2H, dd,
J = 14.4 Hz, 8.4 Hz, HC-H ).
13C-NMR Spectroscopy (D2O, 125 MHz) δ (ppm) =
173.12 (C O), 168.95 (C OOH), 133.50 (ArC ), 129.43 (ArC H),
129.15 (ArC H), 128.03 (ArC H), 54.26 (C H), 52.18 (C H),
38.40 (C H2), 36.75 (C H2), HRMS: calculated mass for
[C24H31N4O6S2]
+: 535.1685, observed mass: 535.1697
2.2. Functionalisation of hyaluronic acid with methacrylic
anhydride
Methacrylate addition procedure utilised previously in
modifying HA.[25] Hyaluronic acid (1 g) was dissolved in
50 mL water. Dimethylformamide (DMF, 30 mL) was
added and the solution stirred until homogeneous. The
polymer solution was then cooled to 5 oC in an ice/water
bath and methacrylic anhydride (740 µL, 5.00 mmol) added
drop-wise over a period of fifteen minutes. The reaction
mixture was removed from the ice bath and the pH main-
tained between 8-10 for 4 h by addition of 0.5 M NaOH(aq)
before being left to stir overnight. The reaction mixture
was then transferred directly to dialysis tubing (MWCO
15 kDa) and dialysed against water for 5 days. The polysac-
charide was then obtained by lyophilisation in yields up-
wards of 88 % and functionalisation with methacrylate ob-
served by 1H NMR. Yield: 880 mg, 88 %; Degree of MA
functionalisation: 15 %;
1H NMR: (D2O, 500 MHz) δ (ppm) = 6.21-5.97 (1H,
s, vinyl-H ), 5.75-5.58 (1H, s, vinyl-H ), 4.56-2.57 (36H, br,
polysaccharide backbone), 2.14-1.69 (9H, s, -NHCOCH 3
and 3H, s, allyl-H ).
2.3. Michael addition of FC-CF to HA-MAs
Hyaluronic acid-methacrylate (HA-MA, 400 mg) was
dissolved in PBS solution (100 mM, 100 mL) and de-
gassed with nitrogen for 1 h in darkness. Separately, FC-
CF (929 mg, 1.54 mmol, ∼10 molar equivalents to MA
residues) was dissolved in water (5 mL) and triethylamine
(1.28 mL, 9.24 mmol, 6.00 eq) added. The peptide precip-
itated on addition of the base and then re-dissolved. The
solution was degassed with nitrogen for 15 min before the
addition of DL-dithiothreitol (DTT, 235 mg, 1.53 mmol,
1 eq). The reaction mixture was stirred for 4 h and then in-
jected into the degassed HA-MA solution and stirred con-
tinuously overnight. The solution was then transferred to
dialysis tubing and dialysed against brine for 3 days and
then water for 2 days. The functional polysaccharide was
then isolated by lyophilisation, degree of functionalisation
estimated by 1H NMR and the consumption of methacry-
late observed to be 100 %. Yield: 332 mg, 83 %; Degree
of CF functionalisation: 10 %;
1H NMR: (D2O, 500 MHz) δ (ppm) = 7.47-7.17 (5H,
m, aryl-H ), 4.57-2.53 (65H, br, polysaccharide backbone),
2.16-1.73 (15H, s, -NHCOCH 3), 1.24-1.04 (3H, s, CH 3).
2.4. Hydrogel formation and drug loading
Before constitution of the hydrogels, all components
and equipment (stirrer bars, vials, etc.) were irradiated
with UV-C (240nm) light for 1 h. HA-CF was dissolved
in cell culture media (defined below) at a concentration
of 20 mg mL-1 (2 wt.%). CB[8] was added (5 mg mL-1,
0.5 wt.%) and the mixture stirred for 2 h until it expressed
viscoelastic properties. At this point either doxorubicin
(Sigma Aldrich) or cisplatin (Cambridge Bioscience Ltd)
was added to the hydrogel at a concentration of 1 mg mL-1
3
(0.1 wt.%) and stirred until homogeneous. FITC-AntiCD44
(human, Miltenyi Biotec Ltd) hydrogel was prepared slightly
differently by dissolving HA-CF polymer in 1 mL of the
purchased antibody solution instead of SF media.
2.5. Culture media
Cells were cultured under serum-free (SF) conditions.
The SF media consisted of phenol-free Neurobasal-A (NBA)
(Invitrogen, UK) with 20 mM L-glutamine, 1% v/v peni-
cillin, streptomycin and fungicid (PSF) solution, 20 ng mL-1
human epidermal growth factor (hEGF, Sigma, UK), 20 ng mL-1
human fibroblast growth factor (hFGF, RD systems, UK),
2% v/v B27 (Invitrogen, UK) and 1% N2 v/v (Invitrogen,
UK). All cell cultures were grown in appropriate incuba-
tors at 37oC in 5% CO2.
2.6. Cell culture
Ethical approval was obtained for use of human ma-
terial LREC ref 04/Q0108/60. Each GB specimen was
anonymized, weighed, cut into small pieces and dissoci-
ated enzymatically using a mixture of Accutase (Invitro-
gen, UK) in HBSS Ca2+ / Mg2+ free. The suspension was
filtered through a 40 µm strainer (Falcon, UK) to isolate
single cells. For removal of red blood cell, the single cell
suspension was washed with filtered red cell lysis buffer
consisting of NH4Cl (8.3 g), KHCO3 (1.0 g) and 5% of
EDTA (1.8 mL) in double distilled (dd) water (1 L). Cells
were rewashed in HBSS Ca2+ / Mg2+ free before quan-
tification of live cells by trypan blue exclusion. Cells were
seeded at standard density of 15,000 cells per cm2 in de-
fined SF medium in 37 oC, 5% CO2 incubator. All primary
cultures monitored daily for primary neurosphere forma-
tion. Primary neurosphere cultures were rewashed and
fed weekly for 2-6 weeks depending on the sample. After
a variable priming period in which primary spheres size
increased, spheres were harvested, washed once in HBSS
Ca2+ / Mg2+ free before being seeded without dissociation
on ECM-coated flasks (Nunc, Thermo Scientific) to grow
as primary monolayer cultures. As the primary monolayer
approached confluence cells were dissociated by incuba-
tion with Accutase at room temperature and washed with
HBSS Ca2+ / Mg2+ free. The cell viability was assessed by
trypan blue exclusion and cells reseeded onto ECM-coated
flasks at a density of 15,000 cells per cm2 to generate the
subsequent monolayers. Cells were grown in 96 well plates,
sterilised coverslips in 24 well plates or in T25 and T75
flasks. Extracellular matrix gel (ECM) from Engelbreth
Holm-Swarm mouse sarcoma (Sigma) was used as adhe-
sive substrate after being dilute 1:10 in phenol-free NBA
(Gibco) before coating the flasks.
2.7. MTT assay for drug delivery experiments
In a typical experiment, cells were seeded at a density
of 40,000 cells per well into 3 24-well plates pre-coated
with ECM and incubated for 2 days in 1 mL of defined
SF media in 37 oC and 5% CO2. There were 6 replicas
in each repeat per cell line. Following incubation, hanging
cell culture inserts (Millipore, PET, 0.4 µm) containing ei-
ther 100 µl of drug loaded hydrogel, hydrogel, drug or SF
media (no treatment). The cells were then incubated for
a further 72 h prior to the removal of the hanging inserts
and addition of 20 µl of MTT solution (Sigma Aldrich)
into each. Following a further incubation period of 4 h,
the media was removed and the purple formazan crystals
solubilized in 500 µl of DMSO. Optical absorbance val-
ues at 570 nm from each well were recorded using a plate
reader. Absorbance values measured from wells contain-
ing no cells were used as blank controls. Percentage cell
viability was then assessed by adjusted absorbance values
whereby the average absorbance values of the control wells
was subtracted from the experimental well values and the
corresponding value then analyzed as a percentage of the
absorbance from the no treatment wells.
2.8. Immunocytochemistry and fluorescent imaging
Preceding treatment with hanging wells loaded with
hydrogel formulations, cells were cultured in 24-well plates
equipped with coverslips. After treatment of the cell lines
for 72 h, hanging wells were removed and the coverslips
washed three times with PBS. The coverslips were then
fixed with ice cold methanol and incubated for 10 min at
4oC. The coverslips were then washed with further PBS
(x3) and then carefully dried by absorbing any residual
fluid with a tissue. Coverslips were then transferred to
petri dishes coated with parafilm to provide a hydrophobic
surface. Blocking buffer (PBS/A) was added to the surface
of the coverslip, left to stand for 45 min and then removed.
Primary antibodies were then added to the cells monolay-
ers at a supplier recommended concentration (75 µl a cov-
erslip) and incubated at RT for 90 min. This solution was
then removed and coverslips washed with PBS (x3) and
secondary fluorescent antibodies added at supplier recom-
mended concentrations and incubated in darkness for a
further 45 min. At this point the liquid was removed from
the coverslip, washed with PBS (x3) followed by doubly
distilled water (x3) and then mounted onto slides with
DAPI containing fluorsave. Imaging was performed by ex-
citing DAPI, rhodamine, doxorubicin and FITC labelled
markers by using the blue, red and green channels fitted
to a fluorescent microscope.
2.9. FITC labelling of HA-CF polymer
To a solution of HA-CF (100 mg) in water (25 mL)
was added fluorescein-isothiocyanate (1 mg) and stirred
overnight in darkness. The reaction mixture was then
transferred to dialysis tubing and immersed in water. The
water was changed three times daily until the dialysis so-
lution no longer had a yellow colour and the polymer was
recovered by lyophilization.
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2.10. Hydrogel implantation and immunocytochemistry
Pieces of human GB tissue were obtained from anonymized
surgical samples. All tissue was obtained with full per-
mission under the relevant national and local authorities,
and with consent of all patients involved. 10 µl of FITC
labelled HA-CF/CB[8] hydrogel with encapsulated rho-
damine B or doxorubicin (0.1 wt.%) was injected into
the centre of the tissue sample. Control samples received
FITC labelled hydrogels without any cargo. Rhodamine
hydrogel tissue samples were then incubated in defined cell
culture media at 37 o C for 24 h, doxorubicin loaded sam-
ples were incubated for 1 h and then fixed by soaking in
4% paraformaldehyde in PBS overnight. The samples were
then cryo-protected by incubating in solutions of increas-
ing sucrose concentrations (10%, 20% and 30%) at 4 oC
overnight. After incubation, tissue samples were embed-
ded in OCT compound with incorporated DAPI, frozen at
-20 oC and then sliced into 15 µm sections using a cry-
otome and mounted onto microscope slides. Slices were
imaged using a fluorescent microscope, exciting at 360 nm,
510 nm, 488 nm and 495 nm for DAPI, rhodamine B, dox-



















































Figure 2: Rheology of brain tumour samples a) storage (G′), loss
(G′′), and complex (G∗) moduli of surgically resected human brain
tissue. A wide distribution of moduli were recorded between 30 and
650 Pa. Inset is brain tissue on rheometer undergoing time-scan with
an 8 mm geometry. b) The range of observed moduli compared to the
achievable hydrogel moduli. Measurements recorded by time scan at
1% strain, 10 rad s−1. Error bars represent 1 standard deviation.
To allow correct selection and tailoring of hydrogel for-
mulations, rheological characterization of freshly excised
human brain tumour tissue was performed (Figure 2a). A
selection of anonymized tissue samples were taken from
two distinct locations in each tumour of three separate
patients. Rheology of the tissue samples was measured at
20 oC to minimize tissue degradation and also limit de-
hydration of the samples.[26] A large degree of variation
between each of the samples was recorded eluding to the
heterogenous biophysical properties of the tissue, partic-
ularly in the case of G′ (elastic component), whereby the
spread of values ranged from 140–620 Pa. Recorded G′′
(viscous component) values were much lower (40–130 Pa)
than G′ as would be expected from such a material. G∗
(complex modulus) values were also collected as a way of
inferring the tissue’s overall resistance to deformation.
The HA-CF/CB[8] hydrogel was formulated such that
the maximum G′ value falls within the range of G′ for the
resected tissue, which was readily accomplished by alter-
ing the HA-CF and CB[8] concentrations (Figure 2b, see
Supporting Information for full rheological characteriza-
tion). A formulation consisting of 2 wt.% HA-CF hydro-
gel cross-linked with 0.5 equivalents of CB[8] (compared to
the pendant Phe groups, 10% functionalization) ensured
that the supramolecular hydrogel was not as stiff as the
brain tissue, thus maintaining and reinforcing good con-
tact at the gel-tissue interface to promote continued drug
diffusion into marginal tissue. Following resection, as the
brain cavity reshapes, the hydrogel will be able to adapt
on account of the difference in G′′ values, i.e. the brain
will likely deform elastically thereby exerting a force on
the hydrogel, which will dissipate by viscous flow.
Temperature dependency was also studied for the HA-
CF/CB[8] hydrogels (Supporting information Figure S1b).
While 1 wt.% HA-CF/CB[8] hydrogels exhibit tempera-
ture sensitivity, 2 wt.% hydrogels are mostly resistant to
temperature change. This is likely on account of two fac-
tors, a larger amount of polymer entanglements arising
from a higher concentration and the increase in concen-
tration of phenylalanine (F) binding units. All hydro-
gel formulations exhibited a frequency dependence with
an increase in moduli as a function of applied oscillatory
frequency, Figure S1c-d. Crossover points of G′ and G′′
occurred at lower frequencies with higher CB[8] concen-
trations, indicative of the CB[8] physical cross-links con-
trolling the level of reordering and restructuring possible
through 2:1 complex formation.
3.1. Therapeutic Delivery
HA-CF/CB[8] hydrogels were applied to primary GB
cell lines derived from several different human patients.
Patient-derived primary cell lines are in vitro models that
are more representative of heterogeneous tumour cell pop-
ulations and can recapitulate many of the histological fea-
tures of the parent tumour.[27, 28] Two structurally dif-
ferent small molecule drug compounds, doxorubicin and
cisplatin, were initially selected for delivery to the cell
lines based on previously reported good activity against
GB in vitro.[29, 30] Drug compounds were loaded into the
hydrogel at a concentration of 0.1 wt.%. This represents
concentrations that are significantly higher than reported
IC50 values for both drugs, and therefore even with a slow
release of drug from the hydrogel, a good therapeutic re-
sponse should be observed.[30] Without a drug loading,
there was no significant cell death from exposure to the
HA-CF/CB[8] hydrogel, which corroborates toxicity find-
ings (Supporting Information Figure S4). Incorporation of
either doxorubicin or cisplatin into the hydrogel led to a
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40–60% drop in viability (Figure 3). Therefore, it is clear
that a cytotoxic amount of chemotherapeutic compound
was delivered from the hydrogel and onto the GB cell
monolayer resulting in cell death. Despite high maximum
deliverable concentrations, decreasing the cell viability to-
ward 0% was not achieved and this could be for a variety
of reasons. It is possible that only a small amount of drug
was released from the gel.[31] However, when comparing
the cargo-loaded hydrogels to drug solutions of the same
concentration, we see a similar final cell viability. Alterna-
tively, as this study uses highly heterogeneous primary cell
populations, it may be that largely resistant fractions are
prevalent in the monolayers, and that these cells survive
treatment. Finally, the drug might react with the HA-CF
polymer and change the release profile (See Supporting
Information for full rationale, Figure S8).
3.2. GB live-cell imaging
Live-cell confocal imaging was undertaken for cells re-
ceiving HA-CF/CB[8] hydrogels loaded with doxorubicin,
Figure 3. Accumulation of fluorescently active doxoru-
bicin (λex=480nm, λem=575nm) within cell nuclei can
be observed (Figure 3).[32] The cells appear to have re-
duced in population with fewer dendrons, indicating an un-
healthy cell culture, compared to control treatments of un-
loaded HA-CF/CB[8]. In both control experiments there
are considerably more cells, with a number appearing to
be ‘rounding off’ for cellular division.[33]
In a second delivery experiment to investigate the abil-
ity of HA-CF/CB[8] hydrogels to deliver larger biomolecules,
FITC-labelled human anti-CD44 antibody (MW=79 kDa),
of which CD44 is a prevalent cell surface marker of GB,[34]
was successfully delivered to the cell monolayers via the
hydrogel (Figure 3).
3.3. Immunocytochemistry
Immunocytochemistry (ICC) was used to image the
GB cell lines for relative visual quantification of prolifer-
ative or inflammatory markers post-exposure to the HA-
CF/CB[8] hydrogel or cargo-loaded hydrogels (Figure 4;
cisplatin-loaded hydrogels in Figure S5). High concentra-
tions of the proliferative markers (SOX2[35], Nestin[36])
are present in the cells that received either no treatment
or were just exposed to the hydrogel formulation (Fig-
ure 4A1-2, B1-2) However, when doxorubicin-loaded hy-
drogels were applied to these lines (Figure 4C1-2), a clear
decrease in these markers was observed. Inflammatory
markers IL1β[37], IL6[38], and TNFα[39] were also stud-
ied. In the control and hydrogel only samples, these mark-
ers are not visible, inferring normal stress or inflamma-
tory levels within the cell. However, the cells exposed to
doxorubicin-loaded hydrogel show clear up-regulation of
IL1β and IL6 in comparison to the untreated lines. TNFα
is prevalent in all cells but is severely up-regulated in those
treated with the doxorubin-loaded hydrogel, providing fur-
ther evidence for increased inflammation and cell stress.




































Figure 3: Live cell imaging of primary GB cells. A) cells following
no treatment. B) cells following exposure to HA-CF/CB[8] hydrogel.
C) cells following treatment with doxorubicin-loaded hydrogel, dox-
orubicin can be seen accumulating within the cells (red areas). D)
FITC-antiCD44 (green) delivered from hydrogel to GB monolayer
resulting in labelling of the cell surface and no detrimental changes
to the cell morphology. Viability of primary GB cell lines following
72 h of exposure to either 2 wt% HA-CF/CB[8] hydrogel alone or
with incorporated doxorubicin(DoxR) or cisplatin (CisP) (0.1 wt%).
Controls were used with DoxR and CisP at the same concentration
in PBS. Cells treated with hydrogel only showed good viability at
the end of the treatment in comparison to controls with no treat-
ment at all (normalized to 100%). Doxorubicin and cisplatin treated
cells saw significant decreases in the viability on account of cytotoxic
chemotherapy effect. Error bars represent one standard deviation,
n=3.
Overall, the ICC results provide further evidence that the
HA-CF/CB[8] hydrogel does not have a negative effect on
the cells when applied in vitro and is likely to be non-toxic
if used in vivo. Moreover, when doxorubicin is loaded into
the hydrogel, a cellular inflammatory response can be in-
duced by diffusion of a chemotherapy from the hydrogel
formulation to the cells.
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Figure 4: Representative fluorescent imaging of primary GB lines
post-treatment with immunocytochemistry staining. A1-3) GB cells
exposed to no treatment. B1-3) cells exposed to hydrogel treatment.
C1-3) cells exposed to hydrogels containing doxorubicin. (See also
supporting information Figure S5 for HA-CF/CB[8] hydrogel con-
taining cisplatin.)
3.4. Drug release studies
The release of doxorubicin from 2 wt.% HACF/CB[8]
hydrogels was quantified using UV/vis spectroscopy, whereby
release media was periodically sampled and cumulative re-
lease of the cargo obtained (Supporting Information Fig-
ure S3). An initial linear bolus release of doxorubicin was
observed within the first 10 h, where 8% of the loaded
cargo was released. Further monitoring up to 50 h demon-
strated a slow release, achieving 11% of the total cargo.
Release rate from supramolecular hydrogels can be altered
in an array of methodologies. Introducing modifications
to parent–polysaccharide Mw, guest moiety kinetics, guest
functionalisation percentage, CB[8] host content and the
formulation conditions allow for fine tuning of the release
kinetics from the hydrogel.[40, 41, 31]
A natural component of the brain that would con-
tribute to the continued release of cargo is hyaluronidase
(HAase).[42] This enzyme can cleave the HA polysaccha-
ride within the material, reducing the moduli of the hydro-
gel (by shortening of the HA backbone), thereby increasing
cargo release, as demonstrated in Figure 5a.
3.5. Ex-vivo tumour injections
To further evaluate the diffusion of compounds from
the hydrogel when injected into tissue, a simple model ex
vivo injection procedure was designed and utilised. In this
experiment, a piece of freshly-resected brain tumour tis-
sue was injected with FITC-labelled HACF/CB[8] hydro-
gel with encapsulated cargo. The samples were incubated
at 37 oC before fixation in paraformaldehyde. Figure 5
shows that the hydrogel itself remains localised at the in-
jection point and does not display diffusion through the
tissue, whereas the rhodamine B or doxorubicin cargo does
diffuse out of the hydrogel and penetrates into the brain
tissue over 24 or 1 h respectively (further rhodamine b
and doxorubicin images in Supporting Information Figure
S6 and S7 respectively). In addition, good apposition be-
tween hydrogel and tissue at their interface is observed in
Figure 5c. Diffusion of rhodamine B into surrounding GB
tissue can be seen up to 1000 µm within 24 h post injection
(Supporting Information Figure S6a). Doxorubicin can be
clearly seen within the cell nuclei within 1 h post-injection
up to 950 µm (Figure 5d). Imaging also seems to delineate
a zone in which nuclei take up only the drug, which may
be considered a dead zone extending to 400 µm. A further
zone in which drug has diffused and is uptaken by the cells
can also be visualized between 400–950 µm.
4. Discussion
4.1. Biocompatibility
The first major hurdle in developing an implantable
drug-delivery device is biocompatibility. It is well known
that due to their high water content (>90%) that hydro-
gels are good candidates for biocompatible materials.[40,
31] HA-CF/CB[8] hydrogels are produced from hyaluronic
acid polysaccharide backbones that are functionalized with
naturally-occurring amino acids.[25] We have demonstrated
that there was no toxicity in vitro associated with the
hydrogels. In fact, inflammatory markers remained low
and viability remained high despite the introduction of
the hydrogels. Only those hydrogels carrying chemother-
apeutic agents showed significant inflammatory response
(Figure 4). Additionally, it was observed during live cell
imaging that cells treated with the HA-CF/CB[8] con-
trol showed good proliferation, and appeared healthy (Fig-
ure 3). While the hydrogel should be able to remain
in the brain for several weeks–months after surgery for
a slow and sustained therapeutic release of its cargo, it
is also important that there is a pathway for eventual
degradation of the material, and that these degradation
products are also biocompatible. Our hyaluronidase en-
zymatic release studies (Figure 5), and previously pub-
lished long-term protein release studies, demonstrate that
release can occur for extended periods of time and that
enzymes present within the brain can degrade the gels.[31]
It is thought that the eventual degraded products would
be oligomeric saccharides (including glucuronic acid)[43],
the dipeptide cysteine-phenylalanine that forms the pen-
dant physical cross-links[25] bound within cucurbit[8]uril
has been shown to cause no significant drop in cell viabil-
ity in vitro in this study, and previously in vivo.[40] These
results suggest that inert polymers can be utilised in an
in vivo setting for treating GB.
4.2. Efficacy
We have demonstrated that HA-CF/CB[8] hydrogels
have the potential to avoid drawbacks present within Gliadel R©
wafers. The hydrogel delivery platform offers a material
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Figure 5: A) Doxorubicin loaded hydrogels were stable for a period of
up to 15 d expressing good retention of doxorubicin cargo at 37 oC.
Addition of 1mL of HAase (5000 U mL−1) in PBS and incubation
for 24 h afforded complete degradation of the hydrogel and release of
the remaining doxorubicin into the now homogeneous free flowing.
Fluorescent microscope imaging of hydrogel injected into human GB
tissue samples. B-C) injection site of hydrogel loaded with doxoru-
bicin. Penetration into the cellular nucleus is observed in red (purple
if DAPI also present) D) radial penetration of doxorubicin (red) from
FITC-HA-CF/CB[8] hydrogel (green). Drug diffusion up to 900 µm
can be observed. A dead zone, of 400 µm, in which only doxorubicin
fluorescence (red) is seen, extends into a diffusion zone in which the
cellular stain DAPI (blue) can be observed.
that is less stiff (lower G′) than brain tissue, affording a hy-
drogel that can maintain tight apposition to tumour tissue
while still being able to adapt to a healing resection cavity
on account of the dynamic response to shear (Figure 5). It
was found that HA-CF/CB[8] hydrogels have lower G′and
higher G′′values than tumour tissue. The greater loss mod-
ulus (G′′) allows for the hydrogel to deform under vis-
cous flow to dissipate the energy from the healing cavity,
actively contributing to the maintenance of the cavity–
hydrogel contact. In addition to being softer than tissue
from human brain (G∗ for the hydrogel can be formulated
to be lower than the surrounding tissue) the ex vivo in-
jection studies demonstrate that HA-CF/CB[8] hydrogels
have excellent suitability towards trans-cranial injection.
We have previously shown that physically cross-linked hy-
drogels lend themselves towards injectable materials on ac-
count of their reversible and transient nature.[31, 40, 25]
The ability to rapidly self-heal, demonstrates the suitabil-
ity towards clinical application. Furthermore, our ex vivo
injection studies demonstrate that the HA-CF/CB[8] hy-
drogels are able to maintain their integrity after injection
into tumour tissue.
By maintaining closer contact with the walls of the re-
section cavity, HA-CF/CB[8] hydrogels could provide slow,
sustained release of therapeutics agents immediately fol-
lowing surgery, targetting a therapeutic opportunity with
a variety of antineoplastic therapies. A window of time
that is not typically used in current GB treatment proto-
cols following surgery and prior to adjuvant CRT.
The therapeutic encapsulation and release properties
need to be tailorable; it should be possible for the ma-
terial’s physical properties to be formulated on demand
in the operating room. Owing to the enzyme-cleavable
polysaccharide backbone, this hydrogel system allows for
a sustained, slow release of synergistic drug compounds.
Surgical staff would be able to formulate the delivery ve-
hicle in the operating theatre with an encapsulated com-
bination of therapies specific to the patient. Thus, HA-
CF/CB[8] hydrogels not only improve on the overall dis-
tance achievable and the rate of drug diffusion,[19] but also
increase the quality and surface area of contact with brain
tissue than is currently possible with Gliadel R© wafers.[22]
We have described a hydrogel drug-delivery platform
for GB and subsequently shown that the HA-CF/CB[8]
hydrogels are less stiff than brain tissue, are mouldable,
malleable, and injectable, are easily tailorable, and are bio-
compatible and biodegradable. These encouraging results
will need to be validated through in vivo viability and ef-
ficacy studies.
We believe that HA-CF/CB[8] hydrogels provide an
effective alternative to carmustine loaded wafers in order
to bypass the BBB and provide synergistic, personalzsed
therapies locally for patients with GB. Ultimately, we hope
to progress to clinical trials with the aim of improving
overall and progression-free survival for patients afflicted
with this disease.
5. Conclusions
It has been shown through a wide variety of techniques,
that HA-CF/CB[8] hydrogels may become strong candi-
dates for drug-delivery vehicles, specifically for GB treat-
ment. By examining the rheological properties of brain
tissue, the biocompatible HA-CF/CB[8] hydrogel can be
tuned to appropriately compliment the surrounding envi-
ronment, ensuring continuous structural and shape remod-
eling that would be coherent with tissue healing. Delivery
of small-molecule drug compounds and larger antibodies
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to primary GB cell lines has been achieved to a promis-
ing degree of efficacy but warrants further development in
this area to maximize release quantities and to tune re-
lease rates. MTT viability assay results have been further
reinforced by microscopic imaging of the cell lines showing
cellular stress and inflammation after drug/hydrogel treat-
ment. Ex vivo injection of cargo loaded HA-CF/CB[8] hy-
drogel into resected human tissue samples demonstrates
efficient apposition of the gel and diffusive release of the
compounds into the surrounding tissue. Future in vivo
experiments will prove to be the real test of the hydrogel
efficacy and the feasibility of such surgical procedures.
6. Data Availability
Datasets related to this article can be found at
10.17863/CAM.22567, hosted at the Cambridge Data Repos-
itory.
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